TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
Solid Tumor
AKT1 (V-akt murine thymoma viral oncogene homolog 1), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), FOXL2 (Forkhead Box L2), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q)
See More ...
Next generation sequencing (NGS)